Previously untargetable, the KRAS G12D mutation—often found in never-smokers—is on the verge of becoming actionable. Emerging specific inhibitors like Zoldanrasib are showing high response rates (over 60%), suggesting a new targeted therapy option for a patient group that previously lacked one.

The primary challenge in combining KRAS inhibitors with immunotherapy is managing toxicity. A severe side effect could force discontinuation of both drugs, thereby sacrificing the potential for a long-term cure from immunotherapy alone. The goal is to avoid trading overall survival for a higher initial response rate.

The focus on KRAS is expanding beyond small molecule inhibitors to diverse immunotherapies. Approaches like TCR T-cells, mRNA vaccines targeting KRAS neoepitopes, and novel amphiphil vaccines are being developed to activate a patient's immune system against their specific cancer mutations.

In frontline clinical trials for KRAS G12C NSCLC, combining olomorasib with pembrolizumab alone yielded a 90% response rate in patients with >50% PD-L1 expression. This surpassed the 78% rate seen when chemotherapy was added, suggesting a more targeted approach may be superior for this specific biomarker-defined subgroup.

In PD-L1 negative KRAS-mutated lung cancer, where standard immunotherapy is less effective, adding a CTLA-4 inhibitor can recover the immune response and create long-term survivors. This makes a triplet or quadruplet regimen the current optimal strategy for this challenging patient subgroup.

For patients with KRAS G12C non-small cell lung cancer, participation in a clinical trial offers access to next-generation inhibitors that are superior to currently approved agents. This presents a unique situation where standard of care is demonstrably behind investigational therapies.

Clinicians avoid combining KRAS inhibitors with immunotherapy before surgery (neoadjuvant) due to the high risk of severe toxicity. Such an adverse event could jeopardize the window for a potentially curative surgery, making the post-surgical (adjuvant) setting the preferred approach for these potent combinations.

For cancers with mutations like BRAF or MET, where both immunotherapy and targeted therapy are viable options, smoking history can guide treatment sequencing. A heavy smoking history suggests immunotherapy may be more effective upfront, whereas targeted therapy might be preferred first for non-smokers due to differences in tumor immunogenicity.

Early data for next-generation KRAS G12C inhibitors combined with immunotherapy shows a doubling of both response rate (to ~75%) and progression-free survival compared to the current standard of chemo-immunotherapy. This dramatic improvement suggests these combinations will rapidly become the new standard of care.